US equities |
MU $1,085.85 ▲+1.95% NVDA $230.66 ▲+1.00% SNDK $1,787.50 ▲+2.74% INTC $120.61 ▲+0.32% GOOGL $339.53 ▼-1.32% TSLA $356.59 ▲+0.50% SPCX $150.25 ▼-0.41% AMD $614.88 ▲+0.51%
FinancialContent Watchlist

Articles published by Zai Lab Limited

< Previous 1 2 3 4 Next >
News headline image
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Changes to Senior Leadership Team
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Updates to China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Participation in Investor Conferences in November and December 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
News headline image
Zai Lab Announces Participation in Investor Conferences in September 2025
From Zai Lab Limited
Via Business Wire
Tickers ZLAB
< Previous 1 2 3 4 Next >